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If you knew that you were going to have one of both of your legs amputated due to a 
preventable medical condition in the future, then any sane person would want to find a way of 
preventing such a disabling and life changing event. Currently peripheral artery disease (PAD) is 
a growing threat to health in modern times, which can lead to the situation mentioned above. Due 
to diet and lifestyle risk factors, PAD incidence has increased as the world has become more 
developed.1 Mankind is unlikely to stop its march onward towards ever more developed states of 
living, which likely will mean even less healthy diets and more sedentary lifestyles in the years 
to come. With the trends as they are, with more than eight million Americans currently suffering 
from PAD and that number actively rising worldwide it is clear that something must be done.2 
While it is not currently agreed upon that PAD screening should be conducted in asymptomatic 
individuals, this is primarily due to the infeasibility of accurately conducting such screens. A 
secondary hurdle is that screening is something that is typically only conducted when there is an 
established methodology for preventing the progression of, or reversing the damage done by, the 
condition. With things as they are, it might seem that there is no hope for PAD screening, but a 
new age is dawning thanks to cutting-edge research.  
 
The Pathophysiology of PAD 
PAD is primarily caused by the progression and proliferation of atherosclerotic plaques 
formed by the collection of lipids in the intimal layer of arteries. The areas that are at greatest 
risk for this are places where the arteries are subjected to lots of stress and movement, and in 
places where they branch or curve and turbulent flow is created. Within these regions, the 
endothelial cells lining the arteries align differently. This hypothetically allows for damage to the 
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endothelial lining to be more likely in these sites than in other locations. Current atherosclerotic 
theory states that when an injury occurs to the endothelial cells, a complex cascade of expression 
and release of chemoattractants and adhesion proteins is started. These proteins then play a role 
in capturing and tethering platelets, lymphocytes, and monocytes that then accumulate at the 
damaged region. These lymphocytes and monocytes then migrate to the intimal layer of the 
vessel. Low density lipoproteins (LDL) then follow this migration and become oxidized. The 
monocytes differentiate to become macrophages and begin releasing proinflammatory substances 
and cytokines. The macrophages then phagocytize the LDL and become foam cells that 
proliferate along with smooth muscle, causing a thickening of the intimal layer. A fibrous cap 
then develops over the lesion leading to progressive stenosis, occlusion, and sometime 
thrombosis. The sequelae of this pathogenic process are claudication, ischemia, and even 
infarction of the affected tissue or limb.  
 
Current PAD Screening 
Currently screening is most commonly performed via ankle brachial index (ABI). ABI is 
a quick and cost-effective test that can be performed in the primary care setting.3 Cost is a major 
determining factor in many aspects of health care and the methodology of PAD screening is no 
exception. While magnetic resonance angiography (MRA) is the undisputed gold standard for 
diagnosing the presence and severity of PAD, its cost is prohibitive. The national average is 
currently approximately $7,000 for imaging of the lower extremities.4 While angiography with 
its many varied forms is agreed upon as the gold standard for confirming a diagnosis of PAD, its 
cost makes its use prohibitive except for in determining the extent of disease severity and 
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viability of revascularization. It is clear why ABI is the preferred screening method when you 
learn that it costs only a little more than $300 on average.5  
 
ABI is a test that is performed by taking the systolic blood pressure in each of a patient’s 
brachial arteries then taking the systolic blood pressure in both of the patient’s dorsalis pedis and 
posterior tibial arteries. You then divide the higher of the two systolic values for each lower 
extremity by the highest systolic value obtained from the upper extremities. ABIs for each lower 
extremity can be calculated in this way. A normal ABI falls in the range of 1.0-1.4. Values above 
1.4 are indicative of a noncompressible calcified vessel, values under 0.9 are diagnostic of PAD. 
In one study when an MRA showing 50% stenosis in pelvic or lower limb arteries was used as a 
reference standard for diagnosable PAD, ABI was found to have a sensitivity of 15% to 20% and 
a specificity of 99%.6 Other studies have demonstrated the same high levels of specificity, yet 
have shown extremely variable levels of sensitivity ranging from 15% to 79%. A concerning fact 
is that the two groups with the lowest ABI sensitivity were found to be diabetics and the 
elderly.7, 8 
 
The Case Against ABI 
  There are further arguments against the use of ABI in addition to its relatively 
cumbersome and time-consuming nature. One such reason is that the test itself has an 80%-85% 
chance of giving a false positive result.9 This is one of the reasons that many are shying away 
from PAD screening because without greater reliability and ease of testing the risk of causing 
untoward physical and psychological harm is too great. Further reason comes from the fact that 
due to unknown physiologic factors there is variability in ABI results for different races.10  
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 Unfortunately, ABI is also often performed and interpreted improperly.5 A reality in modern 
healthcare is that time is the enemy of the clinician and sometimes of proper patient care as well. 
One study cited a lack of time as being the deciding factor for purposely performing ABIs 
incorrectly.11 This admission speaks volumes when you consider that the average ABI when 
properly preformed takes on average only five minutes.12  
 
 
If taking an extra five minutes is enough for clinicians to deem a test too cumbersome to 
be properly performed then regardless of the test’s innate value to patient care, it is essentially 
worthless. It would seem that there must be a better way. The good news is that, thanks to 
cellular adhesion proteins, the answer may be as simple as adding a few more items to the 
patient’s lab orders. 
 
The Role of Cellular Adhesion Proteins 
Endothelial dysfunction has been noted as playing a key role in the development of 
atherosclerotic disease.13 Many plasma markers of endothelial function have been identified and 
are actively being studied for their potential role in PAD screening. One promising feature of 
these plasma markers is that some have been shown to be significantly associated with PAD in 
high risk populations such as African Americans and Hemodialysis patients.14, 15 One of these 
markers, thrombomodulin (TM) is an endothelial glycoprotein that has a role in the protein C 
anticoagulant pathway. Interestingly, the plasma concentration of TM reflects the level of 
endothelial damage, which is logical when one learns that TM has been identified as a marker of 
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microvascular endothelial damage.16, 17, 18 Unsurprisingly,  this was able to be substantiated in a 
2016 study conducted by Tokyo Medical and Dental University.19   
 
Another marker being studied is P-selectin, which is involved in the bonding of 
endothelial cells and the activation, rolling, and attachment of leukocytes.20 In a comprehensive 
study involving over 2,000 participants P-selectin was found to be significantly associated with 
the development of PAD. Not only that, it was also significantly associated with both prevalent 
and incidental PAD, in addition to progression from normal ABI to an ABI less than 0.9.1 Taking 
these correlations one step further P-selectin also has been found to accelerate atherosclerotic 
plaque progression.21 Could perhaps the future of PAD screening lie in the measurement of 
serum concentrations of one or more of these cell adhesion proteins? 
 
How Cellular Adhesion Proteins Change the Game 
While it may be difficult with the current amount of research data to definitively prove 
that either ABI or cellular adhesion plasma markers are a superior modality for PAD screening in 
terms of sensitivity and specificity, what certainly can be determined is that any easy and cost 
effective test like ABI that is not utilized, is inferior to a modality that can offer comparable 
results and is more likely to be used regularly. As the popular sports aphorism goes, “You miss 
100% of the shots that you don’t take.” This can easily be applied to the screening of patients. If 
a test is deemed to be time consuming then it won’t be used in the primary care setting.  
 
It is a well agreed upon fact that longer patient visits yield better results for patient 
outcomes as they allow for more elements of care to be considered and integrated into the 
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treatment plan.22 Clinicians and their clinical teams have an innate sense of this and work within 
the constraints of the modern day healthcare system to bring as much benefit as possible to the 
patient. What this means is trimming the fat and eliminating any part of the visit that is seen by a 
team member as being unnecessary. The consultation with the provider cannot be cut and is 
prioritized over all other parts of the visit. One thing that is often cut from the visits of the 
patients most in need of PAD screening is ABI testing.12 In order to ensure that patients are 
screened for PAD, one potential answer is to have the screening performed when the patient isn’t 
at their primary care provider’s office. 
 
There are few options for when this encounter could happen then without creating 
another separate visit. One place that must be visited in the course of the normal patient care is 
the lab. This required stop offers an excellent place for screening tests to be incorporated. A 
blood draw takes only seconds longer to perform if it is for five tubes of blood to be drawn 
versus two. By taking advantage of this fact the actual testing involved in screening for PAD can 
be moved out of the general practitioner’s office. All a provider need do in that case would be to 
add an order for the cell adhesion proteins that are associated with PAD to the lab slip. 
 
The Future of PAD Screening 
Another benefit of adopting this screening method is that the cost per patient for the lab 
test comes out to only $12.98.23 Based on information from a Health Service Research study and 
the Health Cost Institute it can be extrapolated that the average ABI which takes five minutes on 
average to complete in a primary care PA or NP office costs $30.05 based solely on the time it 
takes.24, 25 This of course doesn’t factor in the cost of the personnel and equipment required to 
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perform the test which is why the actual figure as mentioned is $300 on average. The math 
speaks for itself. Measuring soluble P-selectin has been shown by multiple large scale studies to 
be an effective method for assessing the presence and progression of PAD and offers a 
reasonable alternative to a test modality that no longer seems to offer the most logical solution to 
screening patients.1, 14 The current literature offers droves of evidence for the move towards 
utilizing soluble plasma markers for such a purpose, though there is of course as in any 
burgeoning new field room for further research. The possibilities for the future of these markers 
is bright as they have even been identified as targets for future therapeutic agents to reverse or 
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